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Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as
neoadjuvant chemotherapy in gastro-oesophageal cancer
AA Melcher, D Mort and TS Maughan
Velindre Hospital, Whitchurch, Cardif, CF4 7XL, UK.
Summary High response rates have been reported in the treatment of advanced gastric cancer with epirubicin,
cisplatin and continuous infusion 5-fluorouracil (ECF), including instances of unresectable disease being
rendered operable by chemotherapy. We report our experience with ECF as neoadjuvant treatment in gastric
and lower oesophageal carcinoma. Twenty-seven patients were treated, of whom ten (37%) had carcinoma of
the stomach and 17 (63%) tumours of the lower oesophagus. Histology in the majority ofcases, 21 (78%), was
adenocarcinoma. Before chemotherapy ten patients (37%) had evidence of initially unresectable locally
advanced disease, 16 (59%) had localised disease only and one patient (4%) had a localised primary with a
single liver metastasis. Epirubicin (50 mg m-2 i.v.) and cisplatin (60 mg m-2 i.v.) were administered every 3
weeks for four cycles together with a continuous 12 week infusion of 5-fluorouracil (200 mg m-2 day-').
Fifteen of24 assessable patients (62%) had symptomatic improvement on chemotherapy. On combined surgical
and/or radiological assessment, 15 of the 27 patients (56%) had objective evidence of tumour response. In all
patients assessment for radical surgery was made following chemotherapy. Eighteen patients (67%) proceeded
to operation: of these, 11 had complete resection of their disease, one had a histologically incomplete resection
and six were found to have unresectable disease. No pathological complete responses were observed. Only one
of the ten patients with locally advanced disease achieved complete surgical resection after chemotherapy. At a
median follow-up of 36 months from date ofdiagnosis (range 30-47 months), 19 ofthe 27 patients (70%) have
died. Of 11 patients who had a complete surgical resection, one died post-operatively, three have subsequently
relapsed (of whom two have died) and seven remain disease free. Toxicity from treatment was mild and
included emesis, myelosuppression, stomatitis and exfoliation. Myelosuppression caused modification of
treatment in 14 of 108 chemotherapy cycles (13%). There was one surgical death but no chemotherapy-related
deaths. These early results show encouraging symptomatic and objective responses of gastro-oesophageal
carcinoma to ECF, but provide no instances of ECF achieving complete pathological response. Only
randomised trials can establish the role of neoadjuvant ECF chemotherapy in both initially resectable and
unresectable carcinoma of the stomach and lower oesophagus.
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Adenocarcinoma of the stomach and gastro-oesophageal
junction remains a significant cause of mortality from
malignant disease. Gastric cancer is declining in incidence
(Parkin et al., 1980), but adenocarcinoma of the oesophagus
is on the increase (Powell and McConkey, 1990). Many
patients present with locally advanced inoperable disease, but
even after apparently curative surgery 80-90% of patients
will subsequently relapse (Clarke et al., 1961).
Enthusiasm for more radical (D2) resections for gastric
cancer has waned following the recent increased morbidity
and 10% operative mortality reported in a randomised trial
of 966 patients comparing Dl and D2 resections in a
European population (Bonenkamp et al., 1995). Long-term
survival from this study is awaited.
In view of the limited success with surgery alone, interest
has grown in the use of combined modality treatment,
including chemotherapy. A number of drugs have been
shown to have significant activity as single agents in gastric
adenocarcinoma, including doxorubicin, mitomycin C,
cisplatin, epirubicin and prolonged infusion 5-fluorouracil,
with response rates of between 19% and 36% (reviewed by
Findlay and Cunningham, 1993). Various combination
regimens have been tried in advanced disease with evidence
of improvement in median survival by about 7 months
compared with supportive care alone (Pyrhonen et al., 1992;
Murad et al., 1993). An initial meta-analysis of adjuvant
post-operative chemotherapy showed no improvement in
long-term survival (Hermans et al., 1993), although a more
recent update of this data suggests a small, but significant,
benefit (Hermans and Bonenkamp, 1994).
Subsequently, interest has shifted to neoadjuvant che-
motherapy, which has the theoretical advantage of dealing
with micrometastases at the earliest time, as well as possibly
improving the resectability of local disease. A number of
trials have tested neoadjuvant chemotherapy in both initially
resectable and unresectable gastric cancer with response rates
of between 50% and 80% reported (Findlay and Cunning-
ham, 1993). In one series, 45% of patients with unresectable
disease achieved a complete resection after chemotherapy,
and of these one-third were found to have a pathological
complete-response (Wilke et al., 1989).
The combination of epirubicin, cisplatin and continuous
infusion 5-fluorouracil (ECF) was reported in a phase II
study of 139 patients resulting in a 70% response rate in
advanced gastric cancer (Findlay et al., 1994). A more recent
update of this series from the Royal Marsden Hospital
reports an overall response rate of 61%; of those patients
with locally advanced disease, 66% had complete surgical
resection after ECF, with a histological complete response in
32% (Hill et al., 1995).
In carcinoma of the oesophagus, the poor outcome with
surgery alone has also prompted investigation of combined
modality treatments. There is some evidence to support the
addition of chemotherapy to radiotherapy in locally
advanced disease; in one study, 2 year survival rate was
increased from 10% to 38% (Herskovic et al., 1992). In
adenocarcinoma of the oesophagus, combining chemother-
apy with surgery may be advantageous; in one series of 35
patients with resectable disease, two courses of preoperative
and three or four courses of post-operative etoposide,
fluorouracil and cisplatin (EFP) resulted in a 49% major
response rate, although only one patient had a complete
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pathological response (Ajani et al., 1990). The concept of
neoadjuvant chemotherapy in carcinoma of the oesophagus
is currently being investigated further in an MRC study
(OE02).
We report our experience of ECF as a neoadjuvant
treatment for tumours of both the stomach and lower
oesophagus. Our series includes both patients with initially
inoperable locally advanced disease at presentation, and
those with apparently localised disease on pretreatment
assessment.
Materials and methods
A total of 27 patients referred between January 1992 and
June 1993 with histologically proven tumours of the
stomach or lower oesophagus have been evaluated.
Seventeen (63%) had carcinoma of the distal one-third of
the oesophagus, and ten (37%) had carcinoma of the
stomach. Of the gastric tumours, four were proximal in the
stomach, but these were classified distinct from lower
oesophageal lesions as they arose distal to the gastro-
oesophageal junction.
Patient characteristics are summarised in Table I.
Histological type was adenocarcinoma in all gastric tumours
(10) and in 11 of 17 lower oesophageal tumours. Two
tumours of the lower oesophagus were undifferentiated and
four were squamous cell carcinomas.
All patients were deemed fit for intensive chemotherapy
treatment and were of WHO performance status 0 or 1.
Patients had been initially evaluated by radiological criteria
[barium swallow, computerised tomography (CT) scan],
laparotomy (5/7 patients), endoscopy (25/27), or a combina-
tion of these. Accurate tumour and nodal staging was not
possible, but on initial assessment eight patients (30%) had
invasion of adjacent structures and were therefore T4, and
eight patients (30%) had evidence of nodal involvement. Only
one patient had evidence of distant metastatic disease at
presentation (a stomach primary with a single apparently
resectable liver metastasis). In all patients assessment for
radical surgery was planned, once chemotherapy was
complete. The radical procedures performed were Ivor-
Lewis oesophagogastrectomy for oesophageal primaries, and
total gastrectomy with limited (DI) lymph node dissection for
gastric tumours (together with hemihepatectomy in the
patient with a single liver metastasis).
Table I Patient characterisitcs
Sex
Male 22
Female 5
Age (years)
Mean 54
Range 29-71
Tumour site
Lower oesophagus 17
Stomach 10
Histology
Adenocarcinoma 21
Squamous cell carcinoma 4
Undifferentiated 2
T staging
TI-3 19
T4 8
N staging
NO
N1/2
M staging
MO
Ml
19
8
26
Ten patients (37%) had evidence of initially unresectable
locally advanced disease; five on the basis of findings at
laparotomy and a further five on evidence from CT scanning
suggesting inoperability (coeliac lymphadenopathy, 3; med-
iastinal lymph nodes, 1; and bronchial involvement, 1). The
other 17, including the patient with the single liver metastasis,
had, on radiological criteria, apparently resectable disease
before chemotherapy.
Chemotherapy consisted of epirubicin (50 mg m-2 i.v.)
and cisplatin (60 mg m-2 i.v.) given every 3 weeks for four
cycles together with a continuous 12 week infusion of 5-
fluorouracil (200 mg m-2 day-'). 5-FU was administered via
a central line using a continuous infusion ambulatory pump.
All patients received 1 mg of warfarin daily to prevent
venous thrombosis during treatment.
Initial renal function was measured by [51Cr]EDTA
clearance. Full blood count and serum creatinine were
measured before each cycle and once mid-cycle.
Symptomatic response was monitored by clinical review at
days 1 and 11 of each cycle. Patients' symptoms were scored
as resolved, partially resolved, unchanged or deteriorated.
Further assessment was made by a combination of CT scan
and laparotomy. In 20 patients it was possible to compare
pre- and post-chemotherapy CT scans directly. In four
patients progressive symptoms made repeat CT assessment
for radical treatment inappropriate. Three patients proceeded
to definitive surgery without repeat CT scan. Where
comparison of pre- and post-treatment scans was made,
owing to the difficulty in quantifying tumour extent on CT at
these sites, responses were categorised into three groups only:
significant response, stable disease or progression.
Toxicity from chemotherapy was recorded on haematolo-
gical and biochemical parameters and by regular patient
interview. Following chemotherapy, patients were reassessed
for surgery on the basis of their general condition, response
to treatment and radiology. They proceeded to laparotomy
only if a radical excision was felt to be a possibility. In total,
18 patients proceeded to surgery, of whom 12 underwent
radical resections. In these cases, pathological assessment was
made of disease extent, resection margins and evidence of
necrotic as well as viable tumour.
Results
Patients received between two and eight cycles of ECF
chemotherapy. Fourteen patients completed four cycles of
chemotherapy as planned. Seven patients received fewer than
four cycles (two, two and three patients receiving one, two
and three cycles respectively); in six of these, treatment was
stopped as a result of symptomatic progression and, in the
seventh, following superior vena caval thrombosis. Six
patients had more than the planned four cycles. Five of
these were responding to chemotherapy after four cycles, but
on reassessment remained inoperable; they, therefore,
continued up to a maximum of eight cycles. The patient
with a single liver metastasis received six cycles presurgery to
maximise the observed improvement in both primary and
metastatic disease seen on CT.
Symptomatic and objective response to chemotherapy is
shown in Tables II and III. The major presenting symptom
was dysphagia, in 16 patients, of whom 12 reported their
swallowing significantly better with treatment. Overall
symptoms improved or resolved in 15 of 24 assessable
patients (62%).
Table II Symptomatic repsonse to ECF
Symptom Number Resolved Improved UnchangedProgressed
Dysphagia 16 6 6 1 3
Pain 9 4 0 3 2
Nausea/vomiting 4 2 0 1 1
Haematemesis 2 1 0 0 1ECF as neoadjuvant chemotherapy in gastro-oesophageal cancer
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Table III Objective reponse to ECF
Measure of Stable
response Number Response disease Progression
Clinical only 4 - - 4
CT scan 20 12 5 3
Surgery alone 3 3 -
Overall 27 15 5 7
1.2
> 1.0
.0
co 0.8
0. 0.6
> 0.4
) 0.2
0
In 23 patients, assessment of tumour response was
obtained from CT scanning and/or surgical observation.
Four patients clearly had progressive disease during
chemotherapy on symptoms alone, and further assessment
was not justified. Twenty patients had CT scans before and
after chemotherapy: 12 were documented as significant
response, five as no change and three as disease progres-
sion. A further three patients proceeded to surgery without
repeat CT scanning, but in all these three, significant tumour
regression was felt by the surgeon to have occurred based on
macroscopic appearance at operation compared with pre-
treatment assessment. The summated results show significant
response to chemotherapy in 15 (56%) patients, no change in
five (18%) and disease progression in seven (26%).
Surgery
Surgical outcome is reported according to the initial
assessment of resectability before chemotherapy. Of 17
technically resectable patients before chemotherapy, three
progressed and received no operation. These three all
developed rapid weight loss, in two associated with complete
dysphagia, and in one intractable vomiting; in view of their
rapid deterioration, they were unfit for radical surgery and
were subsequently treated symptomatically only. A total of
11/14 had the tumour resected, of whom 10/11 had a
complete histological excision. In all, 3/14 patients had
unresectable tumours at operation, two owing to locally
advanced disease with lymphadenopathy, and one as a result
of peritoneal seedlings.
Of ten initially unresectable patients, four proceeded to
laparotomy, of whom only one was resectable, complete
excision being achieved.
Pathology
Twelve resected specimens were examined. In 11, excision
appeared histologically complete. In 6 of 12 specimens lymph
nodes were positive for metastatic carcinoma. No pathologi-
cal complete responses were seen.
Survival
At a median follow-up of 36 months, eight of the 27 patients
(30%) are alive, of whom one has recurrent disease. Ten of
the initially resectable group of 17 patients (median survival
10 months) and nine from the unresectable group of ten
patients (median survival 10 months) have died.
All eight surviving patients had a complete surgical
resection. Of these, one was from the initially unresectable
group and presented with coeliac lymphadenopathy, which
resolved on CT scanning following chemotherapy. Six others
also remain disease free, including the patient with a single
liver metastasis at presentation, who is now 41 months from
date of diagnosis, having had gastroesophagectomy and
hemihepatectomy.
Figure 1 shows the survival curve for the group as a whole
and highlights the difference in outcome between those
patients in whom microscopic surgical clearance of disease
was ultimately achieved and those in whom it was not. Three
year survival for patients achieving a pathological complete
excision is 82% (95% confidence interval 58-100%).
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Figure 1 Survival in months after diagnosis.
Toxicity
Toxicity from chemotherapy was acceptable and consisted of
nausea, vomiting, alopecia, mucositis, diarrhoea and exfolia-
tion. In two patients, vomiting was severe enough, despite full
antiemetic cover, to require subsequent dose modification.
Exfoliation, in two patients, and mucositis, in three, were
other side-effects necessitating adjustment in treatment.
The presence of an indwelling central line caused one
episode of axillary vein thrombosis, and one of superior vena
caval thrombosis. Haematological toxicity comprised throm-
bocytopenia (one episode, WHO grade II) and neutropenia,
WHO grade III (six episodes) and grade IV (one episode). In
all, myelosuppression caused modification of treatment in 14
of 108 chemotherapy cycles (13%), although there were no
episodes of neutropenic sepsis during treatment. One patient
died post-operatively from surgical complications following
breakdown of his anastamosis.
Discussion
Neoadjuvant chemotherapy in gastro-oesophageal cancer is a
logical approach to improving surgical resectability and
reducing the incidence of subsequent distant metastatic
disease. Evidence that chemotherapy may render inoperable
disease operable and produce complete pathological re-
sponses provides further encouragement (Wilke et al., 1989).
Our series examined the effect of ECF combination
chemotherapy in both initially resectable and unresectable
tumours of the stomach and lower oesophagus. However, one
major problem in this area is accurately categorising patients
into resectable and unresectable groups. Ideal initial
assessment is by direct surgical vision, but to subject every
patient to laparoscopy or laparotomy would clearly
contribute significantly to treatment morbidity. Five of our
patients with gastric primaries had undergone laparotomy
before chemotherapy, but only as part of a failed attempt at
radical primary surgery. Non-invasive staging by endoscopy,
barium swallow or CT scan cannot provide full information
about local tumour extent or lymph node involvement and,
hence, cannot reliably predict resectability. Endoluminal
oesophageal ultrasonography may provide further informa-
tion about the tumour's depth of invasion and nodal
involvement (Tio et al., 1989), but is not currently available
in our centre.
Within these limitations, 17 of our group of patients were
classified as initially operable, while ten patients had locally
advanced disease on surgical or CT criteria, and were
classified as initially inoperable.
Accurate objective measure of tumour response to
chemotherapy carries the same difficulties as initial assess-
ment, but our overall response rate of 56% compares
favourably with other regimens. The largest series using
ECF in gastric cancer, from the Royal Marsden Hospital
(235 patients), has reported an overall response rate of 61%
....
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(Hill et al., 1995). Our series included histology other than
adenocarcinoma, and, although numbers are small, ECF did
show activity in these patients. Of two undifferentiated
tumours, one achieved a partial response and one a complete
response to chemotherapy. Of four squamous cell carcino-
mas, one progressed, one showed stable disease, one was a
partial and one a complete response. The ultimate measure of
local efficacy is provided by histological assessment in
patients who proceed to surgery; in the Marsden series one-
third of patients achieving complete resection were found to
have no viable tumour in the resection specimen. We did not
see any pathological complete responses, but it may be
significant that our protocol used four cycles of ECF before
surgery as opposed to the Marsden's eight cycles. This may
mean we did not maximise cell death in those patients
responding to chemotherapy. Our reasoning for keeping to
four cycles is that neoadjuvant chemotherapy runs the risk of
delaying definitive surgery in resectable patients, who
subsequently turn out to be non-responders. As our group
included patients with initially localised disease we felt a
planned 12 weeks' chemotherapy was a suitable compromise
between maximising response to treatment and delaying
potentially curative surgery.
Eleven of 17 of our patients assessed to be initially
resectable proceeded to radical surgery. The three who did
not reach laparotomy owing to rapid symptom progression,
and the three who were inoperable at surgery (of whom two
had responded on CT scan to chemotherapy) probably reflect
inaccurate classification as resectable by pretreatment
assessment. In particular, one patient in this group was
unresectable at laparotomy following chemotherapy as a
result of peritoneal seedlings, which may have been excluded
by pretreatment laparoscopy. However, the possibility of
tumour progression during treatment remains a potential risk
of preoperative chemotherapy.
Only one of our unresectable group achieved complete
surgical clearance of their disease following chemotherapy,
which is disappointing when compared with other series in
which chemotherapy has more successfully rendered inoper-
able disease operable (Wilke et al., 1989; Hill et al., 1995).
One reason for this may be that five of our unresectable
group had been classified unresectable at laparotomy, which
may represent a worse prognostic group than those classified
unresectable by radiological means alone. One future
approach in all patients with locally advanced disease may
be to prolong chemotherapy further in responders with the
aim of maximising the chance of a subsequent complete
resection.
Seven of 11 patients who did have complete surgical
clearance after ECF remain disease free at a minimum
follow-up of 30 months (maximum 41 months). Although
longer follow-up is needed, only three have relapsed,
suggesting that micrometastases may indeed have been
effectively treated by neoadjuvant chemotherapy. It is worth
noting that micrometastases may be entirely eradicated by
treatment even when the primary tumour fails to achieve a
complete pathological response, so that providing the
primary is completely resected, long-term disease control
can be achieved, even though viable tumour is seen in the
resected specimen.
Toxicity from chemotherapy was mild and acceptable. The
only treatment-related death was post-surgical and there were
no episodes of neutropenic sepsis. In addition, a symptomatic
response of 62% suggests that ECF can be a useful regimen
in the purely palliative setting.
In summary, neoadjuvant ECF was well tolerated and
produced a 56% response rate in tumours of the stomach and
lower oesophagus. Although there are considerable challenges
in pretreatment assessment of disease, among apparently
resectable patients ECF may improve relapse-free survival. In
our series ECF was disappointing in rendering locally
advanced disease resectable. The challenges now are
accurately staging tumours in this area and selecting patients
appropriately for randomised trials. The MRC Adjuvant
Gastric Infusional Chemotherapy Study (MAGIC) is one
randomised trial presently recruiting, which will assess ECF
given both before and after definitive surgery in operable
stomach cancer.
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